deltatrials
Recruiting PHASE4 INTERVENTIONAL 2-arm NCT06802224

The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery (VEGA-2)

Norepinephrine vs Phenylephrine as the First-line Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-cardiac Surgery

Sponsor: Duke University

Updated 4 times since 2025 Last updated: Mar 10, 2026 Started: Apr 1, 2025 Primary completion: Jul 31, 2028 Completion: Jul 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Acute Kidney Injury (AKI) and Anesthesia and is currently actively recruiting participants. Duke University leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshotNot Yet Recruiting~May 2025 – ~Mar 2026 · 10 months · monthly snapshotRecruiting~Mar 2026 – present · 6 months · monthly snapshotRecruiting

Change History

4 versions recorded
  1. Mar 2026 — Present [monthly]

    Recruiting PHASE4

  2. May 2025 — Mar 2026 [monthly]

    Recruiting PHASE4

    Status: Not Yet RecruitingRecruiting

  3. Mar 2025 — May 2025 [monthly]

    Not Yet Recruiting PHASE4

  4. Feb 2025 — Mar 2025 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Duke University
  • Henry Ford Health System
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • University of California, San Francisco
  • University of Maryland
  • University of Michigan
  • University of Texas Southwestern Medical Center
  • University of Virginia
  • University of Washington
  • Wake Forest University Health Sciences
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .